CHRS

Coherus Oncology, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.54

Price (1 Year)

$2.16 $0.54

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %27.2 / %30
Non-compliant assets / Total market cap %42.7 / %30
Non-compliant revenue / Total income %0 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Website

Analysis (Turkish): CHRS Hissesi Caiz mi, Helal mi? Coherus Oncology, Inc. Katılım Analizi